Ilan Ganot, Solid Bio

Sol­id gets an­oth­er shot in DMD gene ther­a­py race as FDA lifts hold. But is it too late to catch Pfiz­er, Sarep­ta?

Things can get mov­ing again in Worces­ter, Mass­a­chu­setts and Gainesville, Flori­da, where Sol­id Bio­sciences op­er­ate their clin­i­cal sites.

Near­ly a year af­ter the FDA sus­pend­ed Sol­id’s Duchenne mus­cu­lar dy­s­tro­phy gene ther­a­py tri­al over safe­ty con­cerns for a sec­ond time, the agency has giv­en the Cam­bridge biotech the go-ahead to start dos­ing again. The tri­al will like­ly re­sume in the first quar­ter of next year, CSO Carl Mor­ris said in a state­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.